We have collated a list of recommendations from top brokerage firms from ETNow and other sources:
Jefferies on HPCL: Underprform| Target Rs 205
Jefferies maintained an underperform rating on HPCL with a target price of Rs 205. The refining business did better than expected in Q4, it observed.
“Marketing missed estimates, and refining weakness is transitory. There are early signs of recovery,” it added.
The global investment bank sees a possibility of a price cut in diesel/gasoline before key state elections in December.
CLSA on Manappuram Finance: Buy| Target Rs 140
CLSA maintained a buy rating on Manappuram Finance with a target price of Rs 140. Finally, some growth is visible after two-quarters of gold loans but yields fell.
The global investment bank expects Manappuram to deliver single-digit loan growth with modestly improving spreads.
Credit Suisse on Dr Lal Pathlabs: Underperform| Target Rs 1600
Credit Suisse maintained an underperform rating on Dr. Lal Pathlabs with a target price of Rs 1600. The near-term growth is likely to be aided by geographical diversification and higher pricing.
The global investment bank holds ‘Underperform’ owing to the declining trajectory of its EBITDA margin, said the note.
Morgan Stanley on Lupin: Overweight| Target Rs 918
Morgan Stanley upgraded Lupin to Overweight with a target price of Rs 918. The core business has started to show margin improvement from a low base, it said.
“Visibility of high-quality new launches like gSpiriva. FY24 can be a turnaround year for Lupin,” said the note.
(Disclaimer: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of Economic Times)
For all the latest Business News Click Here
For the latest news and updates, follow us on Google News.
